 unit state america
unless otherwis note metric base modelwar
consensu data provid thomson reuter estim
result commentari encourag
manag bullish compani long-term
prospect includ growth driver margin expans
potenti rais estim slightli pt
remain ew valuat
increas ep estim left revenu
unchang rais bump ep
estim follow
estim revis
rais pt remain ew valuat
increas pt old ep new ep
roll forward pt valuat lower
valuat multipl one turn conserv due expect greater
competit companion anim earli next decad
zoeti continu expect simparica trio come market zoeti
confirm section applic safeti efficaci
manufacturing/control file fda applic
current review zoeti state confid simparica trio
efficaci includ full heartworm protect expect approv late
launch ahead spring flea/tick season manag highlight
compani still significantli underrepres oral parasiticid
market given sever year behind competitor launch product
zoeti ad simparica trio repres signific revenu opportun
especi captur higher share term overal oral parasiticid
market expand intern parasiticid
commentari outlook posit well point
derm market share us alreadi management see
opportun expand share larger opportun lie
intern market penetr still rel low
simparica management expect continu growth go
albeit lower rate note could impact new
competitor could launch categori expect higher
seek busi
compani cover morgan stanley research
result investor awar firm may
conflict interest could affect object
morgan stanley research investor consid
morgan stanley research singl factor make
invest decis
analyst certif import disclosur
refer disclosur section locat end
growth ex-u us driven expans dermatolog
market increas market share potenti introduct apoquel
china pend final regulatori approv like sometim
livestock expect speci categori show growth full
year also management also expect cattl market
recov sometim
pipelin launch essenti line extens launch
includ novel product management state call pipelin
mainli relat life cycl innov expect signific
introduct new product program includ life cycl
innov revolut potenti combin revolut
activ ingredi agent
sole neg quarter view pressur base companion
anim busi excl key derm product overal volum growth
base busi continu declin partial off-set price increas
driven competit pressur establish product revolut
parasiticid clavamox anti-infect face competit
new product gener competit
abaxi integr progress well zoeti highlight abaxi deal close
aug integr progress well earli custom respons highli
encourag management also focus build robust diagnost care
team intern util exist zoeti infrastructur drive sale
margin expans like modest given abaxi integr
zoeti continu expect margin expans beyond call
management state guid gross margin approxim
expect continu improv move forward
also expect abl get leverag oper expens
particular continu integr abaxi build make sure
support busi expans may strong
may move forward beyond combin
gross margin expans abl grow expens slower rate
revenu expect abl get margin expans move forward
base case ep current price-to-earnings premium
vs also roughli line w/ average sinc ipo project
bull case ep
bull case ep
new product upsid drive faster revenu growth project zoeti
pursu value-enhanc organ ep upsid plu upsid
yield ep forecast
base case ep
base case ep
project solid double-digit ep growth driven growth
companion anim livestock project compound-annual-growth-rate revenu growth
ep compound-annual-growth-rate easier us livestock comp
global roll-out new product give us confid project
bear case ep
bear case ep
face lower end-market growth greater competit pressur drive
weak financi result share trade compani miss ep estimate
price-to-earnings multipl contract
zoeti combin compel
convers tuck-in option
drive out-performance
ep growth
top-lin growth oper margin
livestock rev demand
meat milk project least doubl
next year due larg part
popul growth increas
affluenc emerg market
companion anim rev
global spend pet grow
quarterli result guidanc updat
new product ramp rel
zoeti becom activ deploy
capit acquir products/compani
competitor perform better/wors
risk achiev price
long-term margin expans fail
new govern regul legisl
impact growth
dollar strength rel foreign
exhibit consensu ntm price-to-earnings vs spec pharma average continu trade larg
premium group
exhibit incom statement margin valuat
sg op exp
sg sale
 sale
short-term invest
a/p accru liabil
total liabil s/e
chang work capit
oper
invest
net chang debt
financ
net chang cash
